Fighting Malignancy in Organ Transplant Recipients

Transplantation Proceedings

Volumn 41, Issue 6 SUPPL., 2009, Pages

  Geissler, E K ^a  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; RAPAMYCIN; TEMSIROLIMUS;

ALLOGRAFT; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER RISK; CLINICAL TRIAL; DNA REPAIR; GRAFT RECIPIENT; HUMAN; IMMUNOREACTIVITY; KIDNEY CARCINOMA; MALIGNANT TRANSFORMATION; NEOPLASM; NONHUMAN; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR MODEL; TUMOR REGRESSION;

HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; ORGAN TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; PROTEIN KINASES; RISK FACTORS;

EID: 67949101918     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2009.06.095     Document Type: Article

References (22)

1. Penn I. Cancers complicating organ transplantation. N Engl J Med 323 (1990) 1767
2. Webster A.C., Craig J.C., Simpson J.M., et al. Identifying high risk groups and quantifying absolute risk of cancer after kidney transplantation: a cohort study of 15 183 recipients. Am J Transplant 7 (2007) 2140
3. Herman M., Weinstein T., Korzets A., et al. Effect of cyclosporine A on DNA repair and cancer incidence in kidney transplant recipients. J Lab Clin Med 137 (2001) 14
4. Hojo M., Morimoto T., Maluccio M., et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 397 (1999) 530
5. Koehl G., Andrassy J., Guba M., et al. Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice. Transplantation 77 (2004) 1319
6. Guba M., von Breitenbuch P., Steinbauer M., et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 8 (2002) 128
7. Grulich A.E., van Leeuwen M.T., Falster M.O., et al. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 370 (2007) 59
8. Thomas G.V., Tran C., Mellinghoff I.K., et al. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med 12 (2006) 122
9. Hambardzumyan D., Becher O.J., Rosenblum M.K., et al. PI3K pathway regulates survival of cancer stem cells residing in the perivascular niche following radiation in medulloblastoma in vivo. Genes Dev 22 (2008) 436
10. Zhou J., Wulfkuhle J., Zhang H., et al. Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance. Proc Natl Acad Sci U S A 104 (2007) 16158
11. Beuvink I., Boulay A., Fumagalli S., et al. The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell 120 (2005) 747
12. Gaumann A., Schlitt H.J., and Geissler E.K. Immunosuppression and tumor development in organ transplant recipients: the emerging dualistic role of rapamycin. Transpl Int 21 (2008) 207
13. Koehl G., Gaumann A., Zuelke C., et al. Development of de novo cancer in p53 knock-out mice is dependent on the type of long-term immunosuppression used. Transplantation 82 (2006) 741
14. Duncan F.J., Wulff B.C., Tober K.L., et al. Clinically relevant immunosuppressants influence UVB-induced tumor size through effects on inflammation and angiogenesis. Am J Transplant 7 (2007) 2693
15. Wulff B.C., Kusewitt D.F., VanBuskirk A.M., et al. Sirolimus reduces the incidence and progression of UVB-induced skin cancer in SKH mice even with co-administration of cyclosporine A. J Invest Dermatol 128 (2008) 2467
16. Hudes G., Carducci M., Tomczak P., et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356 (2007) 2271
17. Stallone G., Schena A., Infante B., et al. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 352 (2005) 1317
18. Campistol J.M., Gutierrez-Dalmau A., and Torregrosa J.V. Conversion to sirolimus: a successful treatment for posttransplantation Kaposi's sarcoma. Transplantation 77 (2004) 760
19. Babel N., Eibl N., Ulrich C., et al. Development of Kaposi's sarcoma under sirolimus-based immunosuppression and successful treatment with imiquimod. Transplant Infect Dis 10 (2007) 59
20. Schena F.P., Pascoe M.D., Alberu J., et al. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 87 (2009) 233
21. Thoreen C.C., Kang S.A., Chang J.W., et al. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem 284 (2009) 8023
22. Lang S.A., Moser C., Fichnter-Feigl S., et al. Targeting heat-shock protein 90 improves efficacy of rapamycin in a model of hepatocellular carcinoma in mice. Hepatology 49 (2009) 523